Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.
It is India’s 1st indigenously developed Receptor Binding Domain Protein sub-unit vaccine against Covid-19
Phase 2 clinical trial to begin in 2022 with participation by Cedars Sinai Medical Center, University of Utah, and City of Hope
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Canada
Darolutamide is developed jointly by Bayer and Orion Corporation
Resolv ER may remedy leading causes of blindness in adults
Nirsevimab is the first investigational long-acting antibody designed to protect all infants for the respiratory syncytial virus season with a single dose
New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong
The three prequalified products are manufactured by the originator company, Roche, but the listings should pave the way for more companies coming forward to seek WHO prequalification
Rimegepant is the first oral calcitonin gene-related peptide receptor antagonist to demonstrate positive results in a pivotal trial in the Asia Pacific
Subscribe To Our Newsletter & Stay Updated
